Dipeptidyl peptidase-4 inhibitors may up pancreatic disease risk

Dipeptidyl peptidase-4 inhibitors may up pancreatic disease risk

(HealthDay)—Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to a study published online Aug. 20 in Diabetes Care.

Minyoung Lee, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues used the Korean National Health Insurance Service-Health Screening Cohort database to identify 33,208 patients with newly diagnosed type 2 diabetes who were treated with antidiabetes drugs from 2007 to 2013. Associations between DPP-4i and pancreatitis and were investigated.

The researchers found that 10,218 patients were new users of DPP-4i and 22,990 were new users of other antidiabetes drugs. There were significantly increased risks for pancreatitis (adjusted hazard ratio, 1.24) and pancreatic (adjusted hazard ratio, 1.81) with DPP-4i. There was a six-month drug use lag period. Within the first 12 months and one year after the initial prescription, the risk for pancreatitis and pancreatic cancer was generally consistent without showing an increasing trend according to exposure duration.

"The absence of according to exposure duration suggests the chances of reverse causality, and long-term pancreatic safety of DPP-4i has to be further investigated," the authors write.


Explore further

Metformin may cut mortality risk in post-pancreatitis diabetes

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2019 HealthDay. All rights reserved.

Citation: Dipeptidyl peptidase-4 inhibitors may up pancreatic disease risk (2019, August 28) retrieved 23 October 2019 from https://medicalxpress.com/news/2019-08-dipeptidyl-peptidase-inhibitors-pancreatic-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more